Reasons and outcomes of olanzapine dose adjustments in the outpatient treatment of schizophrenia

Pharmacopsychiatry

Volumn 42, Issue 4, 2009, Pages 135-140

  Suarez, D ^a   Haro, J M ^a   Novick, D ^b   Perrin, E ^b   Ochoa, S ^a   Naber, D ^c  

^a CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE SALUD MENTAL CIBERSAM   (Spain)

^b ELI LILLY AND COMPANY   (United States)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; OLANZAPINE; BENZODIAZEPINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERPROLACTINEMIA; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OBSERVATIONAL STUDY; OUTPATIENT CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; TARDIVE DYSKINESIA; TREATMENT OUTCOME; TREATMENT RESPONSE; AMBULATORY CARE; CHEMICALLY INDUCED DISORDER; DOSE RESPONSE; DYSKINESIA; FOLLOW UP; MULTICENTER STUDY; REGRESSION ANALYSIS; RISK;

ADULT; AMBULATORY CARE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DYSKINESIAS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; ODDS RATIO; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; SCHIZOPHRENIA; SEXUAL DYSFUNCTION, PHYSIOLOGICAL; TREATMENT OUTCOME;

EID: 70249097750     PISSN: 01763679     EISSN: 14390795     Source Type: Journal    
DOI: 10.1055/s-0028-1112127     Document Type: Article

References (32)

1. Albers LJ, Ozdemir V, Marder SR et al. Low-dose fluvoxamine as an adjunct to reduce olanzapine therapeutic dose requirements: a prospective dose-adjusted drug interaction strategy. J Clin Psychopharmacol 2005 ; 25 : 170-174
2. American Psychiatric Association (APA). Practice guidelines for the treatment of patients with schizophrenia. Washington, DC: APA ; 1997
3. Ascher-Svanum H, Stensland M, Kinon J et al. Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. J Psychopharmacol 2005 ; 19 (6 Suppl) : 110-117
4. Baker RW, Kinon BJ, Maguire GA et al. Effectiveness of rapid initial dose escalation of up to forty milligrams per day of oral olanzapine in acute agitation. J Clin Psychopharmacol 2003 ; 23 : 342-348
5. Bergemann N, Frick A, Parzer P et al. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004 ; 37 : 63-68
6. Breier A, Meehan K, Birkett M et al. A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry 2002 ; 59 : 441-448
7. Chakos M, Lieberman J, Hoffman E et al. Effectiveness of second-generation anti-psychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001 ; 158 : 518-526
8. Chiu CC, Lane HY, Huang MC et al. Dose-dependent alterations in the pharmacokinetics of olanzapine during co-administration of fluvoxamine in patients with schizophrenia. J Clin Pharmacol 2004 ; 44 : 1385-1390
9. Covell NH, Jackson CT, Evans AC et al. Antipsychotic prescribing practices in Connecticut's Public Mental Health System: rates of changing medications and prescribing styles. Schizophr Bull 2002 ; 28 : 17-29
10. Czobor P, Volavka J, Sheitman B et al. Antipsychotic-induced weight gain and therapeutic response: a diff erential association. J Clin Psychopharmacol 2002 ; 22 : 244-251
11. Gorwood P. Meeting everyday challenges: antipsychotic therapy in the real world. Eur Neuropsychopharmacol 2006 ; 16 (Suppl. 3) : 156-162
12. Guy G. Clinical Global Impression. In ECDEU Assessment Manual for Psychopharmacology (Revised). Rockville, Maryland: National Institute of Mental Health ; 1976
13. Haan L, Nimwegen L, Amelsvoort T et al. Improvement of subjective well-being and enduring symptomatic remission, a 5-year follow-up of first episode schizophrenia. Pharmacopsychiatry 2008 ; 41 : 125-128
14. Hanley JA, Negassa A, Edwardes MD et al. Statistical analysis of correlated data using generalized estimating equations: an orientation. Am J Epidemiol 2003 ; 157 : 364-375
15. Haro JM, Edgell ET, Jones PB et al. The European Schizophrenia Outpatient Health Outcomes (SOHO) study: rationale, methods and recruitment . Acta Psychiatr Scand 2003 ; 107 : 222-232
16. Haro JM, Edgell ET, Frewer P, et al., on behalf of the SOHO Study Group. The European Schizophrenia Outpatient Health Outcomes Study: baseline findings across country and treatment. Acta Psychiatr Scand 2003 ; 107 (Suppl. 416) : 7-15
17. Haro JM, Kamath SA, Ochoa S et al. The Clinical Global Impression- Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia. Acta Psychiatr Scand 2003 ; 107 (Suppl. 416) : 16-23
18. Haro JM, Suarez D, Novick D et al. Three-year antipsychotic Effectiveness in the outpatient care of schizophrenia: observational versus randomized studies results. Eur Neuropsychopharmacol 2007 ; 17 : 235-244
19. Hofer A, Hummer M, Huber R et al. Selection bias in clinical trials with antipsychotics. J Clin Psychopharmacol 2000 ; 20 : 699-702
20. Kasper S. Optimisation of long-term treatment in schizophrenia: treating the true spectrum of symptoms. Eur Neuropsychopharmacol 2006 ; 16 (Suppl. 3) : 135-141
21. Kinon BJ, Basson BR, Gilmore JA et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001 ; 62 : 92-100
22. Kinon BJ, Volavka J, Stauffer V et al. Standard and higher dose of olanzapine in patients with schizophrenia or schizoaff ective disorder: a randomized, double-blind, fixed-dose study. J Clin Psychopharmacol 2008 ; 28 : 392-400
23. Lambert M, Haro JM, Novick D et al. Olanzapine versus other antipsychotics in actual outpatient settings: 6-month safety results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005 ; 111 : 232-243 (Pubitemid 40342192)
24. Lipkovich I, Baron D, Houston J et al. Flexible-dose clinical trials. Predictors and outcomes of antipsychotic dose adjustments. J Clin Psychopharmacol 2005 ; 25 : 381-386
25. Mauri M, Simoncini M, Castrogiovanni S et al. A psychoeducational program for weight loss in patients who have experienced weight gain during antipsychotic treatment with olanzapine. Pharmacopsychiatry 2008 ; 41 : 17-23
26. Mauri MC, Colasanti A, Rossattini M et al. A single-blind, randomized comparison of olanzapine at a starting dose of 5 mg versus 20 mg in acute schizophrenia. Clin Neuropharmacol 2006 ; 29 : 126-131
27. Mauri MC, Colasanti A, Rossattini M et al. Ziprasidone outcome and tolerability: a practical clinical trial with plasma drug levels. Pharmacopsychiatry 2007 ; 40 : 89-92
28. Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophr Res 2003 ; 59 : 19-27
29. Stroup TS, Alves WM, Hamer RM et al. Clinical trials for antipsychotic drugs: design conventions, dilemmas and innovations. Nat Rev Drug Discov 2006 ; 5 : 133-146
30. Suarez D, Haro JM. Overview of the findings from the European SOHO study. Expert Rev Neurother 2008 ; 8 : 873-880
31. Thornley B, Adams C. Content and quality of 2000 controlled trials in schizophrenia over 50 years. BMJ 1998 ; 317 : 1181-1184
32. Westheide J, Cohen S, Bender S et al. Sexual dysfunction in psychiatric inpatients the role of antipsychotic medication. Pharmacopsychiatry 2007 ; 40 : 140-145